Skip to Content
A13 / P13
NCODA Oncology and Hematology Meeting Abstracts | Volume 2 | Supplement 2
Publication Date: October 13, 2026

Durable efficacy and safety with lovotibeglogene autotemcel for sickle cell disease

Authors:

Ashish O. Gupta, MBBS, MPH.; Kristina Nelson, PharmD1; Melissa A. Kinney, PhD2; Robert S. Nickel, MD2; Matt Hsieh, MD4; Suhag Parikh, MD5; Heidi Elliot, BS2; Lin Pan, MS2; Khalid Mamlouk, PharmD2; Stacey Rifkin-Zenenberg, DO6; Alexis A. Thompson, MD, MPH7,8; Mark C. Walters, MD9; Anjulika Chawla, MD2; Alexis Leonard, MD4,10; John F. Tisdale, MD4; Julie Kanter, MD11

Organization / Company:

1University of Minnesota, Minneapolis, MN, USA; 2Genetix Biotherapeutics, Somerville, MA, USA; 3Children’s National Hospital, Washington, DC, USA; 4National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA; 5Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, GA, USA; 6Hackensack University Medical Center, Hackensack, NJ, USA; 7Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 9University of California San Francisco Benioff Children’s Hospitals, Oakland, CA, USA; 10St. Jude Children’s Research Hospital, Memphis, TN, USA; 11University of Alabama at Birmingham, Birmingham, AL, USA

NCODA Oncol Hematol Meet Abstr. 2026;2(suppl 2):abstr 13.

Background:

Sickle cell disease (SCD) causes frequent acute pain crises and progressive chronic complications, impacting quality of life (QoL). One-time gene therapy lovotibeglogene autotemcel (lovo-cel), consisting of autologous hematopoietic stem and progenitor cells transduced with the lentiviral vector encoding functional copies of the ß-globin gene (ßA-T87Q), is approved for patients aged ≥12 years.

 

Objectives:
  • Describe the vaso-occlusive event (VOE)-related efficacy outcomes of lovo-cel in SCD, with 89.8% and 95.9% of participants achieving complete resolution of VOEs and severe VOEs, respectively, at 6–18 months post-infusion.
  • Explain how durable efficacy and quality of life improvements with this one-time gene therapy positively impact patients with SCD and inform the multidisciplinary team’s role in long-term care.

 

Purpose:

We report VOE-related efficacy, durability of response, and QoL outcomes among participants treated with lovo-cel in clinical trials using the current commercial manufacturing process.

 

Method:

Data as of July 2025 were pooled from two prospective trials: HGB-206 (Group C; ≥12 to ≤50 years) and HGB-210 (≥2 to ≤50 years). Follow-up of participants treated with lovo-cel is ongoing in LTF-307. VOE-related endpoints were complete resolution of VOEs (VOE-CR) and severe VOEs (sVOE-CR), assessed during months 6–18 post-lovo-cel infusion among participants with ≥4 VOEs at baseline and ≥18 months of follow-up. Treatment durability (VOEs, HbAT87Q expression, red cell indices, biologic markers of hemolysis) and safety were assessed. Patient-Reported Outcomes Measurement

Information System (PROMIS®) QoL outcomes as of July 2024 were evaluated among HGB-206 Group C participants with data available up to 60 months post-lovo-cel.

 

Results:

76 participants (HGB-206, n=43; HGB-210, n=33) initiated mobilization and 63 received lovo-cel; 49/63 were VOE evaluable (median [range] age at enrollment, 23 [12- 38] years; adults [≥18 years], 75.5%; adolescents [≥12 to <18 years], 24.5%). 44/49 (89.8%) achieved VOE-CR and 47/49 (95.9%) achieved sVOE-CR. At last follow-up (median 60.1 [min-max: 18.4-88.5] months), 38/49 (77.6%) remained VOEfree. HbAT87Q expression and improvements in hematologic parameters were robust and sustained at last follow-up. Clinically meaningful improvements in pain intensity, pain interference, and fatigue were observed early and sustained through month 60. Adverse events were generally consistent with myeloablative conditioning and underlying SCD. No lovo-cel–related insertional oncogenesis was observed.

 

Conclusion:

Lovo-cel is durable, safe, and effective for SCD. After treatment, patients experienced a reduction in VOEs and improvements in QoL. Benefits were sustained through last follow-up (≥5 years). No hematologic malignancies occurred using the current manufacturing process. One myelodysplasia case was reported (diagnosis not confirmed), with α-globin chain imbalance, now an exclusion for lovocel treatment, identified as a possible contributing factor. Real-world implementation of lovo-cel treatment requires evaluation by an SCD specialist and referral to a qualified treatment center for long-term multidisciplinary follow-up, including hematologists/oncologists, pharmacists, advanced practice providers, and trained nurses. For optimal outcomes, treatment teams must be familiar with lovo-cel’s treatment pathway and post-infusion requirements.

Funding: Genetix Biotherapeutics.

 

A13 / P13